Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Two brothers from India were each sentenced to 30 months in prison for a scheme to sell counterfeit and adulterated drugs in ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Two Indian nationals were sentenced to 30 months in prison for smuggling counterfeit cancer drugs into the US.

Varda Space Industries has raised $187 million to accelerate drug development in space using microgravity technology.

The participants in the trial – similar to two-thirds of breast cancer patients overall - had tumors that use the hormones estrogen and progesterone to grow. The goal of so-called endocrine therapy is ...

Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

Freshfields is advising Merck on its $10bn acquisition of respiratory-focused pharmaceutical company Verona Pharma, in a ...